細菌性膣炎用OTC薬品の世界市場インサイト及び予測 2027年

【英語タイトル】Global Bacterial Vaginosis OTC Drug Market Insights and Forecast to 2027

QYResearchが出版した調査資料(QYR21DC05523)・商品コード:QYR21DC05523
・発行会社(調査会社):QYResearch
・発行日:2021年11月
・ページ数:129
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥627,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥940,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,254,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは細菌性膣炎用OTC薬品の世界市場の現状について調査・分析し、2027年までの市場を予測しました。細菌性膣炎用OTC薬品の世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模(ピル、ジェル、クリーム、その他)、用途別市場規模(薬局、オンライン、その他)、主要地域別市場規模(北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ)、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。

・細菌性膣炎用OTC薬品の世界市場概要
・メーカー別の競争状況、市場シェア
・細菌性膣炎用OTC薬品の種類別市場規模:ピル、ジェル、クリーム、その他
・細菌性膣炎用OTC薬品の用途別市場規模:薬局、オンライン、その他
・北米の細菌性膣炎用OTC薬品市場規模2016-2027:種類別、用途別、国別(アメリカ、カナダ)
・ヨーロッパの細菌性膣炎用OTC薬品市場規模2016-2027:種類別、用途別、国別(ドイツ、フランス、イギリス)
・アジアの細菌性膣炎用OTC薬品市場規模2016-2027:種類別、用途別、国別(日本、中国、インド、韓国)
・中南米の細菌性膣炎用OTC薬品市場規模2016-2027:種類別、用途別、国別(メキシコ、ブラジル)
・中東・アフリカの細菌性膣炎用OTC薬品市場規模2016-2027:種類別、用途別、国別(トルコ、サウジアラビア)
・企業情報:Bayer、Pfizer、Sanofi、Piramal、Abbott、Galderma、Mission、Alkem、Xiuzheng、Teva、Perrigo、West-Ward、HPGC、Yunnan Baiyao、Starpharma、Novel、Edenvridge
・細菌性膣炎用OTC薬品のバリューチェーン・販売チャネル分析
・細菌性膣炎用OTC薬品の世界市場動向
【レポートの概要】

Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.

Market Analysis and Insights: Global Bacterial Vaginosis OTC Drug Market
The global Bacterial Vaginosis OTC Drug market is valued at US$ million in 2020. The market size will reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.

Global Bacterial Vaginosis OTC Drug Scope and Segment
Bacterial Vaginosis OTC Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Bacterial Vaginosis OTC Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Pill
Gel
Cream
Other

Segment by Application
Pharmacy
On-line
Other

By Company
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

【レポートの目次】

1 Study Coverage
1.1 Bacterial Vaginosis OTC Drug Product Introduction
1.2 Market by Type
1.2.1 Global Bacterial Vaginosis OTC Drug Market Size Growth Rate by Type
1.2.2 Pill
1.2.3 Gel
1.2.4 Cream
1.2.5 Other
1.3 Market by Application
1.3.1 Global Bacterial Vaginosis OTC Drug Market Size Growth Rate by Application
1.3.2 Pharmacy
1.3.3 On-line
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Bacterial Vaginosis OTC Drug Sales Estimates and Forecasts 2016-2027
2.2 Global Bacterial Vaginosis OTC Drug Revenue Estimates and Forecasts 2016-2027
2.3 Global Bacterial Vaginosis OTC Drug Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Bacterial Vaginosis OTC Drug Regions by Sales
2.4.1 Global Top Bacterial Vaginosis OTC Drug Regions by Sales (2016-2021)
2.4.2 Global Top Bacterial Vaginosis OTC Drug Regions by Sales (2022-2027)
2.5 Global Top Bacterial Vaginosis OTC Drug Regions by Revenue
2.5.1 Global Top Bacterial Vaginosis OTC Drug Regions by Revenue (2016-2021)
2.5.2 Global Top Bacterial Vaginosis OTC Drug Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global Bacterial Vaginosis OTC Drug Sales by Manufacturers
3.1.1 Global Top Bacterial Vaginosis OTC Drug Manufacturers by Sales (2016-2021)
3.1.2 Global Top Bacterial Vaginosis OTC Drug Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Bacterial Vaginosis OTC Drug Sales in 2020
3.2 Global Bacterial Vaginosis OTC Drug Revenue by Manufacturers
3.2.1 Global Top Bacterial Vaginosis OTC Drug Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Bacterial Vaginosis OTC Drug Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Bacterial Vaginosis OTC Drug Revenue in 2020
3.3 Global Bacterial Vaginosis OTC Drug Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Bacterial Vaginosis OTC Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Bacterial Vaginosis OTC Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Bacterial Vaginosis OTC Drug Sales by Type
4.1.1 Global Bacterial Vaginosis OTC Drug Historical Sales by Type (2016-2021)
4.1.2 Global Bacterial Vaginosis OTC Drug Forecasted Sales by Type (2022-2027)
4.1.3 Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2016-2027)
4.2 Global Bacterial Vaginosis OTC Drug Revenue by Type
4.2.1 Global Bacterial Vaginosis OTC Drug Historical Revenue by Type (2016-2021)
4.2.2 Global Bacterial Vaginosis OTC Drug Forecasted Revenue by Type (2022-2027)
4.2.3 Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2016-2027)
4.3 Global Bacterial Vaginosis OTC Drug Price by Type
4.3.1 Global Bacterial Vaginosis OTC Drug Price by Type (2016-2021)
4.3.2 Global Bacterial Vaginosis OTC Drug Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global Bacterial Vaginosis OTC Drug Sales by Application
5.1.1 Global Bacterial Vaginosis OTC Drug Historical Sales by Application (2016-2021)
5.1.2 Global Bacterial Vaginosis OTC Drug Forecasted Sales by Application (2022-2027)
5.1.3 Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2016-2027)
5.2 Global Bacterial Vaginosis OTC Drug Revenue by Application
5.2.1 Global Bacterial Vaginosis OTC Drug Historical Revenue by Application (2016-2021)
5.2.2 Global Bacterial Vaginosis OTC Drug Forecasted Revenue by Application (2022-2027)
5.2.3 Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2016-2027)
5.3 Global Bacterial Vaginosis OTC Drug Price by Application
5.3.1 Global Bacterial Vaginosis OTC Drug Price by Application (2016-2021)
5.3.2 Global Bacterial Vaginosis OTC Drug Price Forecast by Application (2022-2027)

6 North America
6.1 North America Bacterial Vaginosis OTC Drug Market Size by Type
6.1.1 North America Bacterial Vaginosis OTC Drug Sales by Type (2016-2027)
6.1.2 North America Bacterial Vaginosis OTC Drug Revenue by Type (2016-2027)
6.2 North America Bacterial Vaginosis OTC Drug Market Size by Application
6.2.1 North America Bacterial Vaginosis OTC Drug Sales by Application (2016-2027)
6.2.2 North America Bacterial Vaginosis OTC Drug Revenue by Application (2016-2027)
6.3 North America Bacterial Vaginosis OTC Drug Market Size by Country
6.3.1 North America Bacterial Vaginosis OTC Drug Sales by Country (2016-2027)
6.3.2 North America Bacterial Vaginosis OTC Drug Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe Bacterial Vaginosis OTC Drug Market Size by Type
7.1.1 Europe Bacterial Vaginosis OTC Drug Sales by Type (2016-2027)
7.1.2 Europe Bacterial Vaginosis OTC Drug Revenue by Type (2016-2027)
7.2 Europe Bacterial Vaginosis OTC Drug Market Size by Application
7.2.1 Europe Bacterial Vaginosis OTC Drug Sales by Application (2016-2027)
7.2.2 Europe Bacterial Vaginosis OTC Drug Revenue by Application (2016-2027)
7.3 Europe Bacterial Vaginosis OTC Drug Market Size by Country
7.3.1 Europe Bacterial Vaginosis OTC Drug Sales by Country (2016-2027)
7.3.2 Europe Bacterial Vaginosis OTC Drug Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific Bacterial Vaginosis OTC Drug Market Size by Type
8.1.1 Asia Pacific Bacterial Vaginosis OTC Drug Sales by Type (2016-2027)
8.1.2 Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Type (2016-2027)
8.2 Asia Pacific Bacterial Vaginosis OTC Drug Market Size by Application
8.2.1 Asia Pacific Bacterial Vaginosis OTC Drug Sales by Application (2016-2027)
8.2.2 Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Application (2016-2027)
8.3 Asia Pacific Bacterial Vaginosis OTC Drug Market Size by Region
8.3.1 Asia Pacific Bacterial Vaginosis OTC Drug Sales by Region (2016-2027)
8.3.2 Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America Bacterial Vaginosis OTC Drug Market Size by Type
9.1.1 Latin America Bacterial Vaginosis OTC Drug Sales by Type (2016-2027)
9.1.2 Latin America Bacterial Vaginosis OTC Drug Revenue by Type (2016-2027)
9.2 Latin America Bacterial Vaginosis OTC Drug Market Size by Application
9.2.1 Latin America Bacterial Vaginosis OTC Drug Sales by Application (2016-2027)
9.2.2 Latin America Bacterial Vaginosis OTC Drug Revenue by Application (2016-2027)
9.3 Latin America Bacterial Vaginosis OTC Drug Market Size by Country
9.3.1 Latin America Bacterial Vaginosis OTC Drug Sales by Country (2016-2027)
9.3.2 Latin America Bacterial Vaginosis OTC Drug Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia

10 Middle East and Africa
10.1 Middle East and Africa Bacterial Vaginosis OTC Drug Market Size by Type
10.1.1 Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Type (2016-2027)
10.1.2 Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Type (2016-2027)
10.2 Middle East and Africa Bacterial Vaginosis OTC Drug Market Size by Application
10.2.1 Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Application (2016-2027)
10.2.2 Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Application (2016-2027)
10.3 Middle East and Africa Bacterial Vaginosis OTC Drug Market Size by Country
10.3.1 Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2016-2027)
10.3.2 Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Overview
11.1.3 Bayer Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Bayer Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Pfizer Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Sanofi Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Piramal
11.4.1 Piramal Corporation Information
11.4.2 Piramal Overview
11.4.3 Piramal Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Piramal Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Piramal Recent Developments
11.5 Abbott
11.5.1 Abbott Corporation Information
11.5.2 Abbott Overview
11.5.3 Abbott Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Abbott Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Abbott Recent Developments
11.6 Galderma
11.6.1 Galderma Corporation Information
11.6.2 Galderma Overview
11.6.3 Galderma Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Galderma Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Galderma Recent Developments
11.7 Mission
11.7.1 Mission Corporation Information
11.7.2 Mission Overview
11.7.3 Mission Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Mission Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Mission Recent Developments
11.8 Alkem
11.8.1 Alkem Corporation Information
11.8.2 Alkem Overview
11.8.3 Alkem Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Alkem Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Alkem Recent Developments
11.9 Xiuzheng
11.9.1 Xiuzheng Corporation Information
11.9.2 Xiuzheng Overview
11.9.3 Xiuzheng Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 Xiuzheng Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Xiuzheng Recent Developments
11.10 Teva
11.10.1 Teva Corporation Information
11.10.2 Teva Overview
11.10.3 Teva Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Teva Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Teva Recent Developments
11.11 Perrigo
11.11.1 Perrigo Corporation Information
11.11.2 Perrigo Overview
11.11.3 Perrigo Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.11.4 Perrigo Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Perrigo Recent Developments
11.12 West-Ward
11.12.1 West-Ward Corporation Information
11.12.2 West-Ward Overview
11.12.3 West-Ward Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.12.4 West-Ward Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 West-Ward Recent Developments
11.13 HPGC
11.13.1 HPGC Corporation Information
11.13.2 HPGC Overview
11.13.3 HPGC Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.13.4 HPGC Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 HPGC Recent Developments
11.14 Yunnan Baiyao
11.14.1 Yunnan Baiyao Corporation Information
11.14.2 Yunnan Baiyao Overview
11.14.3 Yunnan Baiyao Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.14.4 Yunnan Baiyao Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Yunnan Baiyao Recent Developments
11.15 Starpharma
11.15.1 Starpharma Corporation Information
11.15.2 Starpharma Overview
11.15.3 Starpharma Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.15.4 Starpharma Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Starpharma Recent Developments
11.16 Novel
11.16.1 Novel Corporation Information
11.16.2 Novel Overview
11.16.3 Novel Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.16.4 Novel Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Novel Recent Developments
11.17 Edenvridge
11.17.1 Edenvridge Corporation Information
11.17.2 Edenvridge Overview
11.17.3 Edenvridge Bacterial Vaginosis OTC Drug Sales, Price, Revenue and Gross Margin (2016-2021)
11.17.4 Edenvridge Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Edenvridge Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Bacterial Vaginosis OTC Drug Value Chain Analysis
12.2 Bacterial Vaginosis OTC Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Bacterial Vaginosis OTC Drug Production Mode & Process
12.4 Bacterial Vaginosis OTC Drug Sales and Marketing
12.4.1 Bacterial Vaginosis OTC Drug Sales Channels
12.4.2 Bacterial Vaginosis OTC Drug Distributors
12.5 Bacterial Vaginosis OTC Drug Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Bacterial Vaginosis OTC Drug Industry Trends
13.2 Bacterial Vaginosis OTC Drug Market Drivers
13.3 Bacterial Vaginosis OTC Drug Market Challenges
13.4 Bacterial Vaginosis OTC Drug Market Restraints

14 Key Findings in The Global Bacterial Vaginosis OTC Drug Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Bacterial Vaginosis OTC Drug Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Pill
Table 3. Major Manufacturers of Gel
Table 4. Major Manufacturers of Cream
Table 5. Major Manufacturers of Other
Table 6. Global Bacterial Vaginosis OTC Drug Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Bacterial Vaginosis OTC Drug Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 8. Global Bacterial Vaginosis OTC Drug Sales by Region (2016-2021) & (K Units)
Table 9. Global Bacterial Vaginosis OTC Drug Sales Market Share by Region (2016-2021)
Table 10. Global Bacterial Vaginosis OTC Drug Sales by Region (2022-2027) & (K Units)
Table 11. Global Bacterial Vaginosis OTC Drug Sales Market Share by Region (2022-2027)
Table 12. Global Bacterial Vaginosis OTC Drug Revenue by Region (2016-2021) & (US$ Million)
Table 13. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region (2016-2021)
Table 14. Global Bacterial Vaginosis OTC Drug Revenue by Region (2022-2027) & (US$ Million)
Table 15. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region (2022-2027)
Table 16. Global Bacterial Vaginosis OTC Drug Sales by Manufacturers (2016-2021) & (K Units)
Table 17. Global Bacterial Vaginosis OTC Drug Sales Share by Manufacturers (2016-2021)
Table 18. Global Bacterial Vaginosis OTC Drug Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 19. Global Bacterial Vaginosis OTC Drug Revenue Share by Manufacturers (2016-2021)
Table 20. Bacterial Vaginosis OTC Drug Price by Manufacturers 2016-2021 (US$/Unit)
Table 21. Global Bacterial Vaginosis OTC Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Bacterial Vaginosis OTC Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bacterial Vaginosis OTC Drug as of 2020)
Table 23. Bacterial Vaginosis OTC Drug Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Bacterial Vaginosis OTC Drug Product Offered
Table 25. Date of Manufacturers Enter into Bacterial Vaginosis OTC Drug Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Bacterial Vaginosis OTC Drug Sales by Type (2016-2021) & (K Units)
Table 28. Global Bacterial Vaginosis OTC Drug Sales by Type (2022-2027) & (K Units)
Table 29. Global Bacterial Vaginosis OTC Drug Sales Share by Type (2016-2021)
Table 30. Global Bacterial Vaginosis OTC Drug Sales Share by Type (2022-2027)
Table 31. Global Bacterial Vaginosis OTC Drug Revenue by Type (2016-2021) & (US$ Million)
Table 32. Global Bacterial Vaginosis OTC Drug Revenue by Type (2022-2027) & (US$ Million)
Table 33. Global Bacterial Vaginosis OTC Drug Revenue Share by Type (2016-2021)
Table 34. Global Bacterial Vaginosis OTC Drug Revenue Share by Type (2022-2027)
Table 35. Bacterial Vaginosis OTC Drug Price by Type (2016-2021) & (US$/Unit)
Table 36. Global Bacterial Vaginosis OTC Drug Price Forecast by Type (2022-2027) & (US$/Unit)
Table 37. Global Bacterial Vaginosis OTC Drug Sales by Application (2016-2021) & (K Units)
Table 38. Global Bacterial Vaginosis OTC Drug Sales by Application (2022-2027) & (K Units)
Table 39. Global Bacterial Vaginosis OTC Drug Sales Share by Application (2016-2021)
Table 40. Global Bacterial Vaginosis OTC Drug Sales Share by Application (2022-2027)
Table 41. Global Bacterial Vaginosis OTC Drug Revenue by Application (2016-2021) & (US$ Million)
Table 42. Global Bacterial Vaginosis OTC Drug Revenue by Application (2022-2027) & (US$ Million)
Table 43. Global Bacterial Vaginosis OTC Drug Revenue Share by Application (2016-2021)
Table 44. Global Bacterial Vaginosis OTC Drug Revenue Share by Application (2022-2027)
Table 45. Bacterial Vaginosis OTC Drug Price by Application (2016-2021) & (US$/Unit)
Table 46. Global Bacterial Vaginosis OTC Drug Price Forecast by Application (2022-2027) & (US$/Unit)
Table 47. North America Bacterial Vaginosis OTC Drug Sales by Type (2016-2021) & (K Units)
Table 48. North America Bacterial Vaginosis OTC Drug Sales by Type (2022-2027) & (K Units)
Table 49. North America Bacterial Vaginosis OTC Drug Revenue by Type (2016-2021) & (US$ Million)
Table 50. North America Bacterial Vaginosis OTC Drug Revenue by Type (2022-2027) & (US$ Million)
Table 51. North America Bacterial Vaginosis OTC Drug Sales by Application (2016-2021) & (K Units)
Table 52. North America Bacterial Vaginosis OTC Drug Sales by Application (2022-2027) & (K Units)
Table 53. North America Bacterial Vaginosis OTC Drug Revenue by Application (2016-2021) & (US$ Million)
Table 54. North America Bacterial Vaginosis OTC Drug Revenue by Application (2022-2027) & (US$ Million)
Table 55. North America Bacterial Vaginosis OTC Drug Sales by Country (2016-2021) & (K Units)
Table 56. North America Bacterial Vaginosis OTC Drug Sales by Country (2022-2027) & (K Units)
Table 57. North America Bacterial Vaginosis OTC Drug Revenue by Country (2016-2021) & (US$ Million)
Table 58. North America Bacterial Vaginosis OTC Drug Revenue by Country (2022-2027) & (US$ Million)
Table 59. Europe Bacterial Vaginosis OTC Drug Sales by Type (2016-2021) & (K Units)
Table 60. Europe Bacterial Vaginosis OTC Drug Sales by Type (2022-2027) & (K Units)
Table 61. Europe Bacterial Vaginosis OTC Drug Revenue by Type (2016-2021) & (US$ Million)
Table 62. Europe Bacterial Vaginosis OTC Drug Revenue by Type (2022-2027) & (US$ Million)
Table 63. Europe Bacterial Vaginosis OTC Drug Sales by Application (2016-2021) & (K Units)
Table 64. Europe Bacterial Vaginosis OTC Drug Sales by Application (2022-2027) & (K Units)
Table 65. Europe Bacterial Vaginosis OTC Drug Revenue by Application (2016-2021) & (US$ Million)
Table 66. Europe Bacterial Vaginosis OTC Drug Revenue by Application (2022-2027) & (US$ Million)
Table 67. Europe Bacterial Vaginosis OTC Drug Sales by Country (2016-2021) & (K Units)
Table 68. Europe Bacterial Vaginosis OTC Drug Sales by Country (2022-2027) & (K Units)
Table 69. Europe Bacterial Vaginosis OTC Drug Revenue by Country (2016-2021) & (US$ Million)
Table 70. Europe Bacterial Vaginosis OTC Drug Revenue by Country (2022-2027) & (US$ Million)
Table 71. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Type (2016-2021) & (K Units)
Table 72. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Type (2022-2027) & (K Units)
Table 73. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Type (2016-2021) & (US$ Million)
Table 74. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Type (2022-2027) & (US$ Million)
Table 75. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Application (2016-2021) & (K Units)
Table 76. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Application (2022-2027) & (K Units)
Table 77. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Application (2016-2021) & (US$ Million)
Table 78. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Application (2022-2027) & (US$ Million)
Table 79. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Region (2016-2021) & (K Units)
Table 80. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Region (2022-2027) & (K Units)
Table 81. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Region (2016-2021) & (US$ Million)
Table 82. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Region (2022-2027) & (US$ Million)
Table 83. Latin America Bacterial Vaginosis OTC Drug Sales by Type (2016-2021) & (K Units)
Table 84. Latin America Bacterial Vaginosis OTC Drug Sales by Type (2022-2027) & (K Units)
Table 85. Latin America Bacterial Vaginosis OTC Drug Revenue by Type (2016-2021) & (US$ Million)
Table 86. Latin America Bacterial Vaginosis OTC Drug Revenue by Type (2022-2027) & (US$ Million)
Table 87. Latin America Bacterial Vaginosis OTC Drug Sales by Application (2016-2021) & (K Units)
Table 88. Latin America Bacterial Vaginosis OTC Drug Sales by Application (2022-2027) & (K Units)
Table 89. Latin America Bacterial Vaginosis OTC Drug Revenue by Application (2016-2021) & (US$ Million)
Table 90. Latin America Bacterial Vaginosis OTC Drug Revenue by Application (2022-2027) & (US$ Million)
Table 91. Latin America Bacterial Vaginosis OTC Drug Sales by Country (2016-2021) & (K Units)
Table 92. Latin America Bacterial Vaginosis OTC Drug Sales by Country (2022-2027) & (K Units)
Table 93. Latin America Bacterial Vaginosis OTC Drug Revenue by Country (2016-2021) & (US$ Million)
Table 94. Latin America Bacterial Vaginosis OTC Drug Revenue by Country (2022-2027) & (US$ Million)
Table 95. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Type (2016-2021) & (K Units)
Table 96. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Type (2022-2027) & (K Units)
Table 97. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Type (2016-2021) & (US$ Million)
Table 98. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Type (2022-2027) & (US$ Million)
Table 99. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Application (2016-2021) & (K Units)
Table 100. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Application (2022-2027) & (K Units)
Table 101. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Application (2016-2021) & (US$ Million)
Table 102. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Application (2022-2027) & (US$ Million)
Table 103. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2016-2021) & (K Units)
Table 104. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2022-2027) & (K Units)
Table 105. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Country (2016-2021) & (US$ Million)
Table 106. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Country (2022-2027) & (US$ Million)
Table 107. Bayer Corporation Information
Table 108. Bayer Description and Major Businesses
Table 109. Bayer Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 110. Bayer Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Bayer Recent Developments
Table 112. Pfizer Corporation Information
Table 113. Pfizer Description and Major Businesses
Table 114. Pfizer Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 115. Pfizer Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Pfizer Recent Developments
Table 117. Sanofi Corporation Information
Table 118. Sanofi Description and Major Businesses
Table 119. Sanofi Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 120. Sanofi Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Sanofi Recent Developments
Table 122. Piramal Corporation Information
Table 123. Piramal Description and Major Businesses
Table 124. Piramal Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 125. Piramal Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Piramal Recent Developments
Table 127. Abbott Corporation Information
Table 128. Abbott Description and Major Businesses
Table 129. Abbott Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 130. Abbott Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Abbott Recent Developments
Table 132. Galderma Corporation Information
Table 133. Galderma Description and Major Businesses
Table 134. Galderma Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 135. Galderma Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Galderma Recent Developments
Table 137. Mission Corporation Information
Table 138. Mission Description and Major Businesses
Table 139. Mission Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 140. Mission Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Mission Recent Developments
Table 142. Alkem Corporation Information
Table 143. Alkem Description and Major Businesses
Table 144. Alkem Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 145. Alkem Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Alkem Recent Developments
Table 147. Xiuzheng Corporation Information
Table 148. Xiuzheng Description and Major Businesses
Table 149. Xiuzheng Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 150. Xiuzheng Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Xiuzheng Recent Developments
Table 152. Teva Corporation Information
Table 153. Teva Description and Major Businesses
Table 154. Teva Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 155. Teva Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Teva Recent Developments
Table 157. Perrigo Corporation Information
Table 158. Perrigo Description and Major Businesses
Table 159. Perrigo Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 160. Perrigo Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Perrigo Recent Developments
Table 162. West-Ward Corporation Information
Table 163. West-Ward Description and Major Businesses
Table 164. West-Ward Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 165. West-Ward Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. West-Ward Recent Developments
Table 167. HPGC Corporation Information
Table 168. HPGC Description and Major Businesses
Table 169. HPGC Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 170. HPGC Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. HPGC Recent Developments
Table 172. Yunnan Baiyao Corporation Information
Table 173. Yunnan Baiyao Description and Major Businesses
Table 174. Yunnan Baiyao Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 175. Yunnan Baiyao Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Yunnan Baiyao Recent Developments
Table 177. Starpharma Corporation Information
Table 178. Starpharma Description and Major Businesses
Table 179. Starpharma Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 180. Starpharma Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Starpharma Recent Developments
Table 182. Novel Corporation Information
Table 183. Novel Description and Major Businesses
Table 184. Novel Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 185. Novel Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Novel Recent Developments
Table 187. Edenvridge Corporation Information
Table 188. Edenvridge Description and Major Businesses
Table 189. Edenvridge Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 190. Edenvridge Bacterial Vaginosis OTC Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. Edenvridge Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Bacterial Vaginosis OTC Drug Distributors List
Table 195. Bacterial Vaginosis OTC Drug Customers List
Table 196. Bacterial Vaginosis OTC Drug Market Trends
Table 197. Bacterial Vaginosis OTC Drug Market Drivers
Table 198. Bacterial Vaginosis OTC Drug Market Challenges
Table 199. Bacterial Vaginosis OTC Drug Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Bacterial Vaginosis OTC Drug Product Picture
Figure 3. Global Bacterial Vaginosis OTC Drug Market Share by Type in 2020 & 2027
Figure 3. Pill Product Picture
Figure 4. Gel Product Picture
Figure 5. Cream Product Picture
Figure 6. Other Product Picture
Figure 7. Global Bacterial Vaginosis OTC Drug Market Share by Application in 2020 & 2027
Figure 8. Pharmacy
Figure 9. On-line
Figure 10. Other
Figure 11. Bacterial Vaginosis OTC Drug Report Years Considered
Figure 12. Global Bacterial Vaginosis OTC Drug Sales 2016-2027 (K Units)
Figure 13. Global Bacterial Vaginosis OTC Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Bacterial Vaginosis OTC Drug Revenue 2016-2027 (US$ Million)
Figure 15. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 16. Global Bacterial Vaginosis OTC Drug Sales Market Share by Region (2016-2021)
Figure 17. Global Bacterial Vaginosis OTC Drug Sales Market Share by Region (2022-2027)
Figure 18. North America Bacterial Vaginosis OTC Drug Sales YoY (2016-2027) & (K Units)
Figure 19. North America Bacterial Vaginosis OTC Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 20. Europe Bacterial Vaginosis OTC Drug Sales YoY (2016-2027) & (K Units)
Figure 21. Europe Bacterial Vaginosis OTC Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 22. Asia-Pacific Bacterial Vaginosis OTC Drug Sales YoY (2016-2027) & (K Units)
Figure 23. Asia-Pacific Bacterial Vaginosis OTC Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 24. Latin America Bacterial Vaginosis OTC Drug Sales YoY (2016-2027) & (K Units)
Figure 25. Latin America Bacterial Vaginosis OTC Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 26. Middle East & Africa Bacterial Vaginosis OTC Drug Sales YoY (2016-2027) & (K Units)
Figure 27. Middle East & Africa Bacterial Vaginosis OTC Drug Revenue YoY (2016-2027) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Bacterial Vaginosis OTC Drug Sales in 2020
Figure 29. The Top 10 and Top 5 Players Market Share by Bacterial Vaginosis OTC Drug Revenue in 2020
Figure 30. Bacterial Vaginosis OTC Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 31. Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2016-2027)
Figure 32. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2016-2027)
Figure 33. Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2016-2027)
Figure 34. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2016-2027)
Figure 35. North America Bacterial Vaginosis OTC Drug Sales Market Share by Type (2016-2027)
Figure 36. North America Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2016-2027)
Figure 37. North America Bacterial Vaginosis OTC Drug Sales Market Share by Application (2016-2027)
Figure 38. North America Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2016-2027)
Figure 39. North America Bacterial Vaginosis OTC Drug Sales Share by Country (2016-2027)
Figure 40. North America Bacterial Vaginosis OTC Drug Revenue Share by Country (2016-2027)
Figure 41. United States Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 42. Canada Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 43. Europe Bacterial Vaginosis OTC Drug Sales Market Share by Type (2016-2027)
Figure 44. Europe Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2016-2027)
Figure 45. Europe Bacterial Vaginosis OTC Drug Sales Market Share by Application (2016-2027)
Figure 46. Europe Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2016-2027)
Figure 47. Europe Bacterial Vaginosis OTC Drug Sales Share by Country (2016-2027)
Figure 48. Europe Bacterial Vaginosis OTC Drug Revenue Share by Country (2016-2027)
Figure 49. Germany Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 50. France Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 51. U.K. Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 52. Italy Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 53. Russia Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 54. Asia Pacific Bacterial Vaginosis OTC Drug Sales Market Share by Type (2016-2027)
Figure 55. Asia Pacific Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2016-2027)
Figure 56. Asia Pacific Bacterial Vaginosis OTC Drug Sales Market Share by Application (2016-2027)
Figure 57. Asia Pacific Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2016-2027)
Figure 58. Asia Pacific Bacterial Vaginosis OTC Drug Sales Share by Region (2016-2027)
Figure 59. Asia Pacific Bacterial Vaginosis OTC Drug Revenue Share by Region (2016-2027)
Figure 60. China Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 61. Japan Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 62. South Korea Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 63. India Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 64. Australia Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 65. Taiwan Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 66. Indonesia Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 67. Thailand Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 68. Malaysia Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 69. Latin America Bacterial Vaginosis OTC Drug Sales Market Share by Type (2016-2027)
Figure 70. Latin America Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2016-2027)
Figure 71. Latin America Bacterial Vaginosis OTC Drug Sales Market Share by Application (2016-2027)
Figure 72. Latin America Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2016-2027)
Figure 73. Latin America Bacterial Vaginosis OTC Drug Sales Share by Country (2016-2027)
Figure 74. Latin America Bacterial Vaginosis OTC Drug Revenue Share by Country (2016-2027)
Figure 75. Mexico Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 76. Brazil Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 77. Argentina Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 78. Colombia Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 79. Middle East and Africa Bacterial Vaginosis OTC Drug Sales Market Share by Type (2016-2027)
Figure 80. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2016-2027)
Figure 81. Middle East and Africa Bacterial Vaginosis OTC Drug Sales Market Share by Application (2016-2027)
Figure 82. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2016-2027)
Figure 83. Middle East and Africa Bacterial Vaginosis OTC Drug Sales Share by Country (2016-2027)
Figure 84. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue Share by Country (2016-2027)
Figure 85. Turkey Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 86. Saudi Arabia Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 87. UAE Bacterial Vaginosis OTC Drug Revenue (2016-2027) & (US$ Million)
Figure 88. Bacterial Vaginosis OTC Drug Value Chain
Figure 89. Bacterial Vaginosis OTC Drug Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed


【掲載企業】

Bayer、Pfizer、Sanofi、Piramal、Abbott、Galderma、Mission、Alkem、Xiuzheng、Teva、Perrigo、West-Ward、HPGC、Yunnan Baiyao、Starpharma、Novel、Edenvridge

★調査レポート[細菌性膣炎用OTC薬品の世界市場インサイト及び予測 2027年] (コード:QYR21DC05523)販売に関する免責事項を必ずご確認ください。
★調査レポート[細菌性膣炎用OTC薬品の世界市場インサイト及び予測 2027年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆